X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
USA (Orange Book)
Europe
0
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
0
Details:
Rinvoq (upadacitinib), a Janus kinase (JAK) inhibitor that interferes with the JAK-STAT signaling pathway, being developed for the treatment in adults with non-segmental vitiligo.
Lead Product(s): Upadacitinib
Therapeutic Area: Dermatology Product Name: Rinvoq
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 12, 2023
Iran Expo
Not Confirmed
Contact SupplierDetails:
Rinvoq (upadacitinib), a Janus kinase (JAK) inhibitor that interferes with the JAK-STAT signaling pathway, indicated for the treatment of adults with moderately to severely active rheumatoid arthritis, active psoriatic arthritis and atopic dermatitis.
Lead Product(s): Upadacitinib
Therapeutic Area: Gastroenterology Product Name: Rinvoq
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 25, 2023
Iran Expo
Not Confirmed
Contact SupplierDetails:
Rinvoq (upadacitinib) is a selective JAK inhibitor that is being studied in several immune-mediated inflammatory diseases including, hidradenitis suppurativa in the Phase 3 clinical trial.
Lead Product(s): Upadacitinib
Therapeutic Area: Dermatology Product Name: Rinvoq
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 24, 2023
Iran Expo
Not Confirmed
Contact SupplierDetails:
ABBV-599 is a novel fixed-dose combination of the Bruton's tyrosine kinase (BTK) inhibitor elsubrutinib and the Janus kinase (JAK) inhibitor upadacitinib under investigation for the treatment of systemic lupus erythematosus.
Lead Product(s): Elsubrutinib,Upadacitinib
Therapeutic Area: Immunology Product Name: ABBV-599
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 31, 2023
Iran Expo
Not Confirmed
Contact SupplierDetails:
Rinvoq (upadacitinib) is a JAK inhibitor, involved in the process of immune-mediated inflammatory diseases. It has been approved by USFDA for the treatment of moderately to severely active crohn's disease.
Lead Product(s): Upadacitinib
Therapeutic Area: Gastroenterology Product Name: Rinvoq
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 18, 2023
Iran Expo
Not Confirmed
Contact SupplierDetails:
Rinvoq (upadacitinib) is a JAK inhibitor, involved in the process of immune-mediated inflammatory diseases. It has been approved in EU for the treatment of moderately to severely active crohn's disease.
Lead Product(s): Upadacitinib
Therapeutic Area: Gastroenterology Product Name: Rinvoq
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 17, 2023
Iran Expo
Not Confirmed
Contact SupplierDetails:
ABBV-599 is a combination of upadacitinib, a JAK inhibitor and elsubrutinib a bruton tyrosine kinase inhibitor which is being investigated for the treatment of systemic lupus erythematosus.
Lead Product(s): Upadacitinib,Elsubrutinib
Therapeutic Area: Immunology Product Name: ABBV-599
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 23, 2023
Iran Expo
Not Confirmed
Contact SupplierDetails:
Rinvoq (upadacitinib) is a JAK inhibitor which are intracellular enzymes which transmit signals arising from cytokine or growth factor-receptor interactions on the cellular membrane to influence cellular processes of hematopoiesis and immune cell function.
Lead Product(s): Upadacitinib
Therapeutic Area: Gastroenterology Product Name: Rinvoq
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 27, 2023
Iran Expo
Not Confirmed
Contact SupplierDetails:
RINVOQ® (upadacitinib), is a selective JAK inhibitor that is being studied in several immune-mediated inflammatory diseases. Based on enzymatic and cellular assays, RINVOQ demonstrated greater inhibitory potency for JAK-1 vs JAK-2, JAK-3, and TYK-2.
Lead Product(s): Upadacitinib
Therapeutic Area: Immunology Product Name: Rinvoq
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 21, 2022
Iran Expo
Not Confirmed
Contact SupplierDetails:
Primary results from the 12-week U-EXCEL induction study on the efficacy and safety of Rinvoq (upadacitinib) induction therapy in patients with moderate to severe Crohn's disease who had inadequate response or intolerance to conventional or biologic therapy.
Lead Product(s): Upadacitinib
Therapeutic Area: Gastroenterology Product Name: Rinvoq
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 29, 2022
Iran Expo
Not Confirmed
Contact SupplierDetails:
With this approval, RINVOQ® (upadacitinib 15 mg, once daily) is the first and only Janus Kinase (JAK) inhibitor approved to treat patients across the spectrum of axial spondyloarthritis (nr-axSpA and ankylosing spondylitis) in the European Union (EU).
Lead Product(s): Upadacitinib
Therapeutic Area: Rheumatology Product Name: Rinvoq
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 29, 2022
Iran Expo
Not Confirmed
Contact SupplierDetails:
Based on enzymatic and cellular assays, RINVOQ (upadacitinib) demonstrated greater inhibitory potency for JAK-1 vs. JAK-2, JAK-3 and TYK-2. The safety results of upadacitinib were generally consistent with the known safety profile, and no new safety risks observed.
Lead Product(s): Upadacitinib
Therapeutic Area: Gastroenterology Product Name: Rinvoq
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 29, 2022
Iran Expo
Not Confirmed
Contact SupplierDetails:
In human cellular assays, RINVOQ (upadacitinib 45 mg [induction dose] and 15 mg and 30 mg [maintenance doses]) preferentially inhibits signalling by JAK1 or JAK1/3 with functional selectivity over cytokine receptors that signal via pairs of JAK2.
Lead Product(s): Upadacitinib
Therapeutic Area: Gastroenterology Product Name: Rinvoq
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 26, 2022
Iran Expo
Not Confirmed
Contact SupplierDetails:
CHMP positive opinion is based on results from the Phase 3 SELECT-AXIS 2 study showing upadacitinib (RINVOQ®) met the primary endpoint of ASAS40 response at week 14 versus placebo.
Lead Product(s): Upadacitinib
Therapeutic Area: Immunology Product Name: Rinvoq
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 27, 2022
Iran Expo
Not Confirmed
Contact SupplierDetails:
Results from study demonstrated significantly greater improvements in signs and symptoms, pain, function, disease activity, health-related quality of life, and MRI-detected SI joint inflammation with upadacitinib (RINVOQ®) compared to placebo at week 141.
Lead Product(s): Upadacitinib
Therapeutic Area: Immunology Product Name: Rinvoq
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2022
Iran Expo
Not Confirmed
Contact SupplierDetails:
Data from three studies publication reports the efficacy and safety results of two induction studies and a maintenance study evaluating clinical remission and endoscopic improvement with oral Rinvoq (upadacitinib) versus placebo over 8 weeks and 52 weeks.
Lead Product(s): Upadacitinib
Therapeutic Area: Gastroenterology Product Name: Rinvoq
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 27, 2022
Iran Expo
Not Confirmed
Contact SupplierDetails:
SELECT-AXIS 2 highlights efficacy and safety data of upadacitinib (RINVOQ®) in patients with non-radiographic axial spondyloarthritis, and in patients with radiographic axial spondyloarthritis with an inadequate response to biologic disease-modifying antirheumatic drugs.
Lead Product(s): Upadacitinib
Therapeutic Area: Immunology Product Name: Rinvoq
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 24, 2022
Iran Expo
Not Confirmed
Contact SupplierDetails:
RINVOQ is selective and reversible JAK inhibitor that is being studied in several immune-mediated inflammatory diseases.15-20 In human cellular assays, upadacitinib inhibits signalling by JAK1 or JAK1/3.
Lead Product(s): Upadacitinib
Therapeutic Area: Gastroenterology Product Name: Rinvoq
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 23, 2022
Iran Expo
Not Confirmed
Contact SupplierDetails:
In patients with Crohn's disease who achieved clinical response showed, a significantly greater proportion treated with either upadacitinib achieved clinical remission, a,b endoscopic response, and endoscopic remission at week 52 compared to placebo.
Lead Product(s): Upadacitinib
Therapeutic Area: Gastroenterology Product Name: Rinvoq
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 11, 2022
Iran Expo
Not Confirmed
Contact SupplierDetails:
Across the two pivotal trials, RINVOQ delivered rapid and meaningful disease control with nearly half of ankylosing spondylitis (AS) patients achieving ASAS40 (51% and 44.5% with RINVOQ versus 26% and 18.2% with placebo) at week 14 compared to placebo.
Lead Product(s): Upadacitinib
Therapeutic Area: Immunology Product Name: Rinvoq
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 29, 2022
Iran Expo
Not Confirmed
Contact SupplierDetails:
RINVOQ (upadacitinib), a selective JAK inhibitor that is being studied in several immune-mediated inflammatory diseases.Based on enzymatic and cellular assays, RINVOQ demonstrated greater inhibitory potency for JAK-1 vs JAK-2, JAK-3, and TYK-2.
Lead Product(s): Upadacitinib
Therapeutic Area: Immunology Product Name: Rinvoq
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Allergan Aesthetics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 21, 2022
Iran Expo
Not Confirmed
Contact SupplierDetails:
RINVOQ (upadacitinib), achieved clinical remission at weeks 8 and 52, the primary endpoint based on the mMS: stool frequency subscore ≤ 1 and not greater than Baseline, rectal bleeding subscore = 0, endoscopy subscore of ≤ 1 without friability, compared to placebo.
Lead Product(s): Upadacitinib
Therapeutic Area: Gastroenterology Product Name: Rinvoq
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 16, 2022
Iran Expo
Not Confirmed
Contact SupplierDetails:
Consistent with results from the U-EXCEED induction study, higher proportion of patients receiving upadacitinib 45 mg also achieved steroid-free clinical remissiond per CDAI and per SF/AP compared to placebo at week 12 among patients taking corticosteroids at baseline.
Lead Product(s): Upadacitinib
Therapeutic Area: Gastroenterology Product Name: Rinvoq
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 24, 2022
Iran Expo
Not Confirmed
Contact SupplierDetails:
Rinvoq (upadacitinib), is a selective and reversible JAK inhibitor Is being studied in several immune-mediated inflammatory diseases promotes histologic and endoscopic mucosal healing in pivotal Phase 3 trial for the treatment of Ulcerative colitis.
Lead Product(s): Upadacitinib
Therapeutic Area: Immunology Product Name: Rinvoq
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 01, 2022
Iran Expo
Not Confirmed
Contact SupplierDetails:
Approval of two dose strengths of Rinvoq (15 mg and 30 mg) supported by efficacy and safety data from one of the largest registrational Phase 3 programs in atopic dermatitis, with more than 2,500 patients evaluated across three studies.
Lead Product(s): Upadacitinib
Therapeutic Area: Dermatology Product Name: Rinvoq
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 14, 2022
Iran Expo
Not Confirmed
Contact SupplierDetails:
Submissions supported by Phase 3 study in which upadacitinib (RINVOQ®) demonstrated significant improvements in signs and symptoms as well as physical function and disease activity versus placebo.
Lead Product(s): Upadacitinib
Therapeutic Area: Immunology Product Name: Rinvoq
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 07, 2022
Iran Expo
Not Confirmed
Contact SupplierDetails:
Approval backed by two Phase 3 clinical studies where RINVOQ ( Upadacitinib) showed efficacy across multiple measures of disease activity in active psoriatic arthritis (PsA) with a safety profile consistent with that seen in rheumatoid arthritis.
Lead Product(s): Upadacitinib
Therapeutic Area: Immunology Product Name: Rinvoq
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 14, 2021
Iran Expo
Not Confirmed
Contact SupplierDetails:
Rinvoq (Upadacitinib), selective and reversible JAK inhibitor achieved both primary endpoints of clinical remission and endoscopic response at week 12 in adults with moderate to severe Crohn's disease.
Lead Product(s): Upadacitinib
Therapeutic Area: Gastroenterology Product Name: Rinvoq
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 06, 2021
Iran Expo
Not Confirmed
Contact SupplierDetails:
The results of this study showed a higher rate of major adverse cardiac events (MACE), malignancy, mortality and thrombosis in XELJANZ (a Janus kinase (JAK) inhibitor) versus RINVOQ®, TNF blockers.
Lead Product(s): Upadacitinib
Therapeutic Area: Immunology Product Name: Rinvoq
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 03, 2021
Iran Expo
Not Confirmed
Contact SupplierDetails:
Of patients treated with RINVOQ who lost CDAI remission, 58% remained in CDAI LDA, and 22% recaptured remission by the analysis cut-off date. Similar patterns of sustained response were observed for remission and LDA based on Simplified Disease Activity Index criteria.
Lead Product(s): Upadacitinib
Therapeutic Area: Immunology Product Name: Rinvoq
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2021
Iran Expo
Not Confirmed
Contact SupplierDetails:
RINVOQ® (upadacitinib) is a selective and reversible JAK inhibitor that is being studied in several immune-mediated inflammatory diseases. SELECT-AXIS 2 is the first trial to evaluate efficacy and safety of upadacitinib in non-radiographic axial spondyloarthritis.
Lead Product(s): Upadacitinib
Therapeutic Area: Immunology Product Name: Rinvoq
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 07, 2021
Iran Expo
Not Confirmed
Contact SupplierDetails:
RINVOQ® (upadacitinib) is a selective and reversible JAK inhibitor that is being studied in several immune-mediated inflammatory diseases. SELECT-AXIS 2 is the first trial to evaluate efficacy and safety of upadacitinib in non-radiographic axial spondyloarthritis.
Lead Product(s): Upadacitinib
Therapeutic Area: Immunology Product Name: Rinvoq
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 07, 2021
Iran Expo
Not Confirmed
Contact SupplierDetails:
RINVOQ (Upadacitinib) is a selective and reversible JAK inhibitor that is being studied in several immune-mediated inflammatory diseases. Upadacitinib has the potential to be an important new treatment option for people with ulcerative colitis.
Lead Product(s): Upadacitinib
Therapeutic Area: Gastroenterology Product Name: Rinvoq
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 16, 2021
Iran Expo
Not Confirmed
Contact SupplierDetails:
RINVOQ (upadacitinib) is a selective and reversible JAK inhibitor that is being studied in several immune-mediated inflammatory diseases. In human cellular assays, RINVOQ preferentially inhibits signaling by JAK1 or JAK1/3 with functional selectivity over cytokine receptors.
Lead Product(s): Upadacitinib
Therapeutic Area: Dermatology Product Name: Rinvoq
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 24, 2021
Iran Expo
Not Confirmed
Contact SupplierDetails:
Additionally, upadacitinib demonstrated statistically significant greater efficacy across all ranked secondary endpoints compared to dupilumab through week 16, including early reduction in itch and rates of skin clearance improvement.
Lead Product(s): Upadacitinib
Therapeutic Area: Dermatology Product Name: Rinvoq
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 04, 2021
Iran Expo
Not Confirmed
Contact SupplierDetails:
Discovered and developed by AbbVie scientists, RINVOQ is a selective and reversible JAK inhibitor that is being studied in several immune-mediated inflammatory diseases.
Lead Product(s): Upadacitinib
Therapeutic Area: Dermatology Product Name: Rinvoq
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 16, 2021
Iran Expo
Not Confirmed
Contact SupplierDetails:
In this study, adults with moderate to severe ulcerative colitis who achieved a clinical response following an 8-week study period of once-daily upadacitinib induction treatment were re-randomized to receive upadacitinib 15mg, 30mg or placebo for an additional 52 weeks.
Lead Product(s): Upadacitinib
Therapeutic Area: Gastroenterology Product Name: Rinvoq
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 29, 2021
Iran Expo
Not Confirmed
Contact SupplierDetails:
Across 3 studies, both doses of RINVOQ met all primary and secondary endpoints, demonstrating rapid and significant improvement in skin clearance and reduction in itch compared to placebo at week 16 and other time points in patients with moderate to severe atopic dermatitis.
Lead Product(s): Upadacitinib
Therapeutic Area: Immunology Product Name: Rinvoq
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 25, 2021
Iran Expo
Not Confirmed
Contact SupplierDetails:
The publication of Measure Up 1 and Measure Up 2 presents the results of efficacy and safety of patients with AD treated with upadacitinib, in monotherapy either with topical corticosteroids (CT).
Lead Product(s): Upadacitinib
Therapeutic Area: Dermatology Product Name: Rinvoq
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 10, 2021
Iran Expo
Not Confirmed
Contact SupplierDetails:
SELECT-PsA 2 is a Phase 3, multicenter, randomized, double-blind, parallel-group, placebo-controlled study designed to evaluate the safety & efficacy of RINVOQ in adult patients with active psoriatic arthritis who have a history of inadequate response to at least one biologic.
Lead Product(s): Upadacitinib
Therapeutic Area: Immunology Product Name: Rinvoq
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 02, 2021
Iran Expo
Not Confirmed
Contact SupplierDetails:
Patients with blood CPK increase were usually asymptomatic and no cases of rhabdomyolysis were reported.1 Serious adverse events occurred at 10.9 events per 100 patient years (100PY) for RINVOQ compared to 14.1 events/100PY for HUMIRA.
Lead Product(s): Upadacitinib
Therapeutic Area: Immunology Product Name: Rinvoq
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 02, 2021
Iran Expo
Not Confirmed
Contact SupplierDetails:
Phase 3 trials of RINVOQ in atopic dermatitis, axial spondyloarthritis, Crohn's disease, ulcerative colitis, giant cell arteritis & Takayasu arteritis are ongoing. RINVOQ in atopic dermatitis is not approved & its safety & efficacy are under evaluation.
Lead Product(s): Upadacitinib
Therapeutic Area: Dermatology Product Name: Rinvoq
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 24, 2021
Iran Expo
Not Confirmed
Contact SupplierDetails:
AbbVie received an information request from the FDA for an updated assessment of the benefit-risk profile for upadacitinib in atopic dermatitis.
Lead Product(s): Upadacitinib
Therapeutic Area: Dermatology Product Name: Rinvoq
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 02, 2021
Iran Expo
Not Confirmed
Contact SupplierDetails:
In SELECT-PsA 1, RINVOQ™ (upadacitinib, 15 mg and 30 mg) improved key joint and skin symptoms up to 24 weeks, including enthesitis. Both doses of upadacitinib significantly improved fatigue compared to placebo at week 12.
Lead Product(s): Upadacitinib
Therapeutic Area: Immunology Product Name: Rinvoq
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 01, 2021
Iran Expo
Not Confirmed
Contact SupplierDetails:
Discovered and developed by AbbVie scientists, RINVOQ is an oral, once daily, selective and reversible JAK inhibitor studied in several immune-mediated inflammatory diseases. It was engineered to have greater inhibitory potency for JAK1 versus JAK2, JAK3 and TYK2.
Lead Product(s): Upadacitinib,Methotrexate
Therapeutic Area: Immunology Product Name: Rinvoq
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 17, 2021
Iran Expo
Not Confirmed
Contact SupplierDetails:
Upadacitinib, a selective and reversible JAK inhibitor discovered and developed by AbbVie, is being studied as an oral therapy for moderate to severe ulcerative colitis and several other immune-mediated diseases.
Lead Product(s): Upadacitinib
Therapeutic Area: Gastroenterology Product Name: Rinvoq
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 22, 2021
Iran Expo
Not Confirmed
Contact SupplierDetails:
RINVOQ (15 mg, once daily) is the first oral, once-daily, selective and reversible JAK inhibitor approved for three adult rheumatic indications in the European Union: rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.
Lead Product(s): Upadacitinib,Methotrexate
Therapeutic Area: Immunology Product Name: Rinvoq
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 25, 2021
Iran Expo
Not Confirmed
Contact SupplierDetails:
Across pivotal clinical trial programs, RINVOQ (15 mg, once daily) demonstrated efficacy across multiple measures of disease activity in psoriatic arthritis (PsA) and ankylosing spondylitis (AS), with a safety profile consistent with that seen in rheumatoid arthritis.
Lead Product(s): Upadacitinib
Therapeutic Area: Immunology Product Name: Rinvoq
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 11, 2020
Iran Expo
Not Confirmed
Contact SupplierDetails:
Significantly more upadacitinib-treated (45 mg) patients achieved clinical remission (primary endpoint per Adapted Mayo Score) at week 8 compared to placebo in adults with moderate to severe ulcerative colitis.
Lead Product(s): Upadacitinib
Therapeutic Area: Gastroenterology Product Name: Rinvoq
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 09, 2020
Iran Expo
Not Confirmed
Contact SupplierDetails:
In its guidance, NICE recommends upadacitinib, in combination with methotrexate for people with severe active RA, where their disease has responded inadequately to, or they are intolerant to at least two conventional disease-modifying anti-rheumatic drugs (DMARDs).
Lead Product(s): Upadacitinib,Methotrexate
Therapeutic Area: Immunology Product Name: Rinvoq
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 06, 2020
Iran Expo
Not Confirmed
Contact Supplier
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
